Intellia has reported positive results from its ongoing Phase I/II trial of NTLA-2002, a CRISPR-based gene editing therapy ...

OKYO Pharma has initiated the Phase II trial of OK-101, a treatment for neuropathic corneal pain (NCP), by dosing the first ...

Germany-based Ottobock SE & Co. KGaA will hold an approximate 10% stake in Onward’s share capital following the investment.

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral GLP-1R agonist, Rybelsus, ...

AngioDynamics has teamed up with the University College London Hospital (UCLH) in the UK to launch a prospective registry ...

There are currently no licensed vaccines to treat norovirus, a highly contagious virus that causes sickness and diarrhoea.

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Over the past few days at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) 2024 in Chicago, US, the ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...

The study will evaluate the company’s Gen-3 Halo headset as an at-home treatment for mild traumatic brain injury.

Galderma has reported positive data from a Phase III clinical trial of RelabotulinumtoxinA for treating frown lines and ...

Otsuka has reported positive interim results from its Phase III trial evaluating sibeprenlimab, a treatment for adults with ...